Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Details) - Schedule of potential common shares

v3.23.1
Net Loss Per Share (Details) - Schedule of potential common shares - shares
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total common stock equivalents 4,931,647 4,566,247
Conversion of Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total common stock equivalents [1] 856,720 956,464
Warrants to Purchase Common Stock and Redeemable Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total common stock equivalents [1] 853,330 853,330
PSUs, RSUs and Options to Purchase Common Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total common stock equivalents [1] 2,638,264 2,173,120
Right to Receive Earnout Shares [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total common stock equivalents 583,333 583,333
[1] Prior period results have been adjusted to reflect the Reverse Stock Split at a ratio of 1-for-30 that became effective April 24, 2023. See Note 1, “Description of Business and Basis of Presentation,” for details.